Genoskin is a biotechnology company based in Toulouse and Boston (USA). The company specializes in the generation of human data for the biotechnology, pharmaceutical, cosmetic and chemical industries.
Genoskin has developed the first ex vivo platform to test the toxicity and efficacy of drug candidates administered by intradermal or subcutaneous injections.
Combined with artificial intelligence and machine learning technologies, Genoskin's platforms generate human data even before clinical trials to reduce the cost, time and risks inherent in drug development.
To do this, we use patented technologies to bio-stabilize human skin tissue from plastic surgeries. Our immunocompetent human skin models are the closest systems to what can be observed in the clinic and are a reliable alternative to animal testing.